Injections of Macrophage Activating Factor May Have the Potential to Cure Cancer Patients with Minimal Residual Disease – and Now Can be Self-Administered by Patients

There is now strong reason to suspect that a natural protein, made in our bodies to boost the microbe- and cancer-fighting abilities of immune cells known as macrophages, can help to cure cancer when injected repeatedly by cancer patients who have minimal disease following successful surgery, chemotherapy, or radiotherapy.  This agent – macrophage activating factor (abbreviated as “GcMAF”) also may have the potential to slow cancer spread in patients with more advanced cancers, although this is more speculative.  And the good news is that, although GcMAF hasn’t yet received drug approval (and may be unlikely to, owing to the fact that it is a natural compound), it currently can be ordered via email from several chemical companies, who ship it in a form suitable for intramuscular administration (much like insulin).

The reason why GcMAF may be especially helpful to cancer patients is that many cancers – perhaps most or all – make an enzyme called nagalase that acts to degrade and prevent the production of this factor within tumors.  Fortunately, this nefarious influence of nagalase can be overcome by injection of adequate doses of pre-formed GcMAF.

The Japanese-American doctor who discovered the cancer fighting role of GcMAF, Dr. Nobuto Yamamoto, has also presented evidence that serum nagalase assays can be very useful for monitoring cancer status.  This reflects his discovery that almost all cancers make nagalase, and that serum nagalase levels tend to correlate with the mass of cancer cells within the body.  Nagalase levels are also elevated in the presence of certain viral infections, such as HIV (since some viruses make a nagalase-like activity), and patients with the rare autoimmune disease SLE also have elevated levels for unknown reasons, but, in patients who are fighting cancer, elevated serum nagalase is likely to be a marker for the continued presence of cancer.  In such patients, it can be monitored to determine whether cancer is spreading or regressing.

Oftentimes, especially soon after initial cancer diagnosis, treatment with surgery, often assisted with adjuvant chemotherapy or radiotherapy, can achieve a remission, such that residual cancer cannot be documented by radiological techniques such as CAT or PET scans.  Nonetheless, such patients often still harbor microscopic nests of cancer cells that have the strong potential to grow back to cause a cancer recurrence – often in a disseminated form not susceptible to surgical cure.  A nagalase assay may often be able to detect such cancer, confirming that a patient needs to keep on fighting the cancer.  And in some patients, more standard cancer markers can confirm the presence of microscopic disease (for example, PSA in prostate cancer patients who have received a prostatectomy).

Dr. Yamamoto has published three provocative clinical studies (targeting patients with breast, colorectal, and prostate cancer) suggesting that, in patients who still have microscopic residual cancer after therapy, as confirmed by assay of serum nagalaase, a series of weekly intramuscular injections of GcMAF (in the tiny dose of 100 nanograms) is often associated with a continual gradual drop in nagalase levels, presumably indicative of macrophage-mediated killing off of the residual cancer cells.  If these injections are continued until nagalase falls into the normal range, a durable cure of cancer is often seen.  In this way, adjuvant GcMAF therapy, guided by nagalase assays, may greatly enhance the curative potency of  properly done surgery, chemotherapy, and radiotherapy.

Whether GcMAF administration can help patients with more extensive disease is more speculative, as no clinical studies pertinent to this have yet been published.  However, rodent studies, as well as logic, suggest that GcMAF may be able to slow down cancer is some of these cases.  Theoretically, GcMAF and other effective immunotherapies should be most effective in patients with microscopic cancer, as the immune system is best capable of coping with small nests of cancer cells, rather than bulky tumors.

In light of these findings, if you are a cancer patient who has recently had successful surgery (and or chemo- or radiotherapy), such that your doctor can’t find residual cancer using radiological tests, it might be prudent to have your serum nagalase tested to determine whether you still have residual cancer.  And if an assay of serum nagalase indicates that your nagalase is elevated, you should give strong consideration to undertaking a series of GcMAF injections – along with whatever other therapy your doctor thinks would be appropriate for addressing this residual disease.  (Note that a negative nagalase assay will not necessarily mean that you don’t have residual cancer – but it would be consistent with this possibility.)

This course of action is now feasible because assays of serum nagalase can be obtained from a clinical lab in New Jersey; see: http://www.gcmaf.eu/info/index.php?option=com_content&view=article&id=130&Itemid=61. You will need to ship a properly drawn blood sample to this lab, and will also need the written permission of a doctor for this assay, which currently costs about 50 Euros.  If your assays come back positive, and you would like to try a series of GcMAF injections, we are aware of at least two chemical laboratories from which GcMAF can be obtained by mail order, shipped in a form suitable for intramuscular self-administration.  Here are the websites of these laboratories: http://www.gcmaf.eu/info/; http://www.saisei-mirai.or.jp/gan/macrophage_eng.html. It is our impression, based on Dr. Yamamoto’s clinical publications, and anecdotal reports, that most patients tolerate standard GcMAF therapy – 100 ng GcMAF administered intramuscularly once weekly – without important side effects.  A small minority of patients may experience mild flu-like symptoms for several days after the injection.  The injections themselves are easy to do – much like insulin injections – and can be done by the patient; in other words, patients can treat themselves with it, with or without the approval of a doctor.  At presence there is no evidence that GcMAF therapy might exert important adverse effects in the long term – and bear in mind that GcMAF is produced normally in the body – but at this point we can’t rule out the possibility that in the future some adverse effects will be identified.  Hence, it probably isn’t prudent to use GcMAF frivolously – but if you are faced with the prospect of recurrent cancer, it may be reasonable to accept a certain amount of theoretical risk to combat it effectively.

By continuing to monitor nagalase – follow-up assays at two month intervals are recommended – you may be able to determine whether a course of GcMAF is doing its job of eliminating cancer.  If nagalase progressively declines during GcMAF therapy, it would seem prudent to continue the injections until nagalase finally drops to the range found in normal healthy people.

GcMAF therapy is not cheap, and currently the expense must be borne by the patient, as GcMAF is not an approved drug.   If you inject GcMAF at 100 ng once weekly, this will cost you $600 or less per month at current prices.  This amount will be difficult for many people with limited incomes, but it is quite modest compared to the cost of many recently-approved cancer drugs.  We do not have the impression that the labs supplying GcMAF are doing so to profiteer off of desperate cancer patients.

If you would like to learn more about the GcMAF and nagalase story, Dr. Tim Smith of Sebastopol California has written an excellent, easy-to-understand monograph about it that is posted online here: http://gcmaf.timsmithmd.com/.  Like us, Dr. Smith is a disinterested analyst, and does not profit from sales of GcMAF.   In addition, our Research Director Mark McCarty has written a more technical essay summarizing and analyzing the research literature on GcMAF and nagalase; this might be of interest to your doctor: —————

Abstracts of Dr. Yamamoto’s major clinical publications are also available online, and may be of interest to your doctor:

http://www.ncbi.nlm.nih.gov/pubmed/17935130; http://www.ncbi.nlm.nih.gov/pubmed/18058096; http://www.ncbi.nlm.nih.gov/pubmed/18633461; http://www.ncbi.nlm.nih.gov/pubmed/8665521.   Full copies (pfds) of two of these pages can also be downloaded online.

We emphasize that we have no financial interest in GcMAF or nagalase assays, and that we cannot guarantee that GcMAF therapy will benefit any given patient.  We are writing this because we have a sincere conviction that many cancer patients, especially those who currently have miminal disease, might be able to save their own lives by availing themselves of GcMAF therapy guided by nagalase assay.  We are not gurus, and future experience might prove us wrong, but this is our honest opinion.

Comments are closed.